期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 68, 期 3, 页码 1125-1150出版社
IOS PRESS
DOI: 10.3233/JAD-181219
关键词
Amyloid-beta; amyloid-beta protein precursor; lysine; neurodegeneration; therapeutics; ubiquitination
Intracellular accumulation of aggregated amyloid-beta, misfolded and non-functional proteinopathy, is the hallmark feature in Alzheimer's disease (AD). There are several mechanisms to clear the amyloid burden in a cell, including transcytosis across the blood-brain barrier, immune mediated, lysosomal pathway associated autophagy, enzymatic degradation by insulin degrading enzyme/neprilysin, and the proteasomal pathway. Among them, the ubiquitin proteasome system (UPS) is playing a critical role to prevent the intracellular amyloid-beta deposition and to clear off the cellular burden in association with ubiquitin E3 ligase enzymes in AD. For ubiquitination, lysine moiety in a protein acts like a docking site for the attachment of ubiquitin molecule and different lysine residues act differently in this reaction. Therefore, it is pertinent to understand and link the role of various lysine residues along with their effector molecules, for instance, E3 ligases PARK2 and STUB1 in the ubiquitination cascade. Herein, we 1) modeled the structure of A beta PP and determined its topologies and studied the impact of lysine residues in A beta PP stability, 2) reported K351 as the most promising target for A beta PP ubiquitination, 3) investigated the plausible role of lysine residues in non-covalent interactions mediated ubiquitin positioning in the ubiquitination, 4) detected conserved amino acids that is crucial for A beta PP ubiquitination, and 5) identified the key ubiquitination enzymes and their interaction network playing major role in the ubiquitination of A beta PP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据